Adolescent sexually transmitted diseases: Recent developments

Current Infectious Disease Reports

Volumn 6, Issue 2, 2004, Pages 141-148

  Blake, Diane R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CIPROFLOXACIN; DOXYCYCLINE; HERPES VACCINE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; VACCINE; VALACICLOVIR; VIRUS VACCINE;

ADOLESCENT DISEASE; ANTIBIOTIC RESISTANCE; ARTHROPATHY; CHLAMYDIASIS; CLINICAL TRIAL; CONDYLOMA; CYTOLOGY; DIAGNOSTIC PROCEDURE; DISEASE TRANSMISSION; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; GENITAL HERPES; GONORRHEA; HEALTH CARE COST; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION PREVENTION; INFECTION RATE; NONHUMAN; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW; SCREENING TEST; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS CULTURE; WART VIRUS; WESTERN BLOTTING;

EID: 3142670546     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-996-0011-y     Document Type: Review

References (48)

1. Alexander LL, Cates JR, Herndon N, Ratcliffe JM: Sexually transmitted diseases in America: how many cases and at what cost? Menlo Park, CA: Kaiser Family Foundation; 1998.
2. Centers for Disease Control and Prevention: Sexually Transmitted Diseases Surveillance, 2002. Atlanta, GA: US Department of Health and Human Services; 2003.
3. Centers for Disease Control and Prevention: Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections-2002. MMWR Morb Mortal Wkly Rep 2002, 51:9-14.
4. United States Preventive Services Task Force: Screening: chlamydial infection. http://www.ahcpr.gov/clinic/uspstf/uspschlm.htm. Accessed September 25, 2003.
5. Burstein GR, Zenilman JM: Non-gonococcal urethritis-a new paradigm. Clin Infect Dis 1999, 28(Suppl 1):S66-S73.
6. Burstein GR, Zenilman JM, Gaydos CA, et al.: Predictors of repeat Chlamydia trachomatis infections diagnosed by DNA amplification testing among inner city females. Sex Transm Infect 2001, 77:26-32.
7. Corey L, Wald A: Genital herpes. In Sexually Transmitted Diseases, edn 3, Edited by Holmes KK, Sparling PF, Mardh PA, et al. New York: McGraw-Hill; 1999:285-312.
8. Lafferty WE, Downey L, Celum C, Wald A: Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis 2000, 181:1454-1457.
9. Armstrong GL, Schillinger J, Markowitz L, et al.: Incidence of herpes simplex virus type 2 infection in the United States. Am J Epidemiol 2001, 153:912-920.
10. Xu F, McQuillan GM, Kottiri BJ, et al.: National seroprevalence and trends in herpes simplex virus type 1 and type 2 infection in the United States, 1988-2000. In Programs and abstracts in the 15th Biennial Congress of the International Society for Sexually Transmitted Diseases 2003. Ottawa: International Society for Sexually Transmitted Diseases; 2003:58-59.
11. Wald A, Zeh J, Selke S, et al.: Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Eng J Med 2000, 342:844-850.
12. De Villiers EM: Taxonomic classification of papillomaviruses. Papillomavirus Rep 2001, 12:57-63.
13. Munoz N, Bosch FX, de Sanjose S, et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003, 348:518-527.
14. Moscicki AB, Hills N, Shiboski S, et al.: Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001, 285:2995-3002.
15. Moscicki AB, Shiboski S, Broering J, et al.: The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998, 132:277-284.
16. Nsuami M, Migel E, Brooks BN, et al.: Screening for sexually transmitted diseases during preparticipaton sports examination of high school adolescents. J Adolesc Health 2003, 32:336-339.
17. Kettle H, Cay S, Brown A, Glasier A: Screening for Chlamydia trachomatis infection is indicated for women under 30 using emergency contraception. Contraception 2002, 66:251-253.
18. Mertz KJ, Voigt RA, Hutchins K, et al.: Findings from STD screening of adolescents and adults entering corrections facilities. Sex Transm Dis 2002, 29:834-839.
19. Van Leeuwen JM, Rietmeijer CA, LeRoux T, et al.: Reaching homeless youths for Chlamydia trachomatis and Neisseria gonorrhoeae screening in Denver, Colorado. Sex Transm Infect 2002, 78:357-359.
20. Kahn RH, Moseley KE, Thilges JN, et al.: Community-based screening and treatment for STDs: results from a mobile clinic initiative. Sex Transm Dis 2003, 30:654-658.
21. Stamm WE: Chlamydia trachomatis infections in the adult. In Sexually Transmitted Diseases, edn 3. Edited by Holmes KK, Sparling PF, Mardh PA, et al. New York: McGraw-Hill; 1999:407-422.
22. Hook EW III, Handsfield HH: Gonococcal infections in the adult. In Sexually Transmitted Diseases, edn 3. Edited by Holmes KK, Sparling PF, Mardh PA, et al. New York: McGraw-Hill; 1999:451-466.
23. Wang LY, Burstein GR, Cohen DA: An economic evaluation of a school-based sexually transmitted disease screening program. Sex Transm Dis 2002, 29:737-745.
24. Ginocchio RH, Veenstra DL, Connell FA, Marrazzo JM: The clinical and economic consequences of screening young men for genital chlamydial infection. Sex Transm Dis 2003, 30:99-106.
25. Mrus JM, Biro F, Huang B, Tsevat J: Evaluating adolescents in juvenile detention facilities for urogenital chlamydial infection. Arch Pediatr Adolesc Med 2003, 157:696-702.
26. Blake DR, Gaydos CA, Quinn TC: Cost-effectiveness analysis of screening adolescent males for chlamydia on admission to detention. Sex Transm Dis 2004, 31:85-95.
27. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2002, 51:1-78.
28. Ashley RL: Sorting out the new HSV type specific antibody tests. Sex Transm Infect 2001, 77:232-237.
29. Ribes JA, Smith A, Hayes M, et al.: Comparative performance of herpes simplex virus type 1-specific serologic assays from MRL and Meridian diagnostics. J Clin Microbiol 2002, 40:1071-1072.
30. Ribes JA, Hayes M, Smith A, et al.: Comparative performance of herpes simplex virus type 2-specific serologic assays from Meridian diagnostics and MRL diagnostics. J Clin Microbiol 2001, 39:3740-3742.
31. Ashley RL, Wald A, Eagleton M: Premarket evaluation of the POCkit HSV-2 type-specific serologic test in culture-documented cases of genital herpes simplex virus type 2. Sex Transm Dis 2000, 27:266-269.
32. Prince HE, Ernst CE, Hogrefe WR: Evaluation of an enzyme immunoassay system for measuring herpes simplex virus (HSV) type 1-specific and HSV type 2-specific IgG antibodies. J Clin Lab Anal 2000, 14:13-16.
33. Hubbard RA: Human papillomavirus testing methods. Arch Pathol Lab Med 2003, 127:940-945.
34. Schiffman M, Solomon D: Findings to date from the ASCUS-LSIL triage study (ALTS). Arch Pathol Lab Med 2003, 127:946-949.
35. Centers for Disease Control and Prevention: Sexually Transmitted Diseases Surveillance Report Supplement: Gonococcal Isolate Surveillance Project (GISP) Annual Report-2001. Atlanta, GA: US Department of Health and Human Services; 2002.
36. Burstein GR, Berman SM, Blumer JL, Moran JS: Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does benefit outweigh risk? Clin Infect Dis 2002, 35:S191-S199.
37. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae-Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep 2002, 51:1041-1044.
38. Cipro (ciprofloxacin hydrochloride) tablets and Cipro (ciprofloxacin) oral suspension. In Physicians' Desk Reference, edn 57. Montvale, NJ: Thompson PDR; 2003:875-885.
39. Centers for Disease Control and Prevention: Notice to readers: discontinuation of cefixime tablets-United States. MMWR Morb Mortal Wkly Rep 2002, 51:1052.
40. Centers for Disease Control and Prevention: Oral alternatives to cefixime for the treatment of uncomplicated Neisseria gonorrhoeae urogenital infections. http://www.cdc.gov/STD/treatment/Cefixime.htm. Accessed October 12, 2003.
41. Steiner KC, Davila V, Kent CK, et al.: Field-delivered therapy increases treatment for chlamydia and gonorrhea. Am J Public Health 2003, 93:882-884.
42. Schillinger JA, Kissinger P, Calvet H, et al.: Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized controlled trial. Sex Transm Dis 2003, 30:49-56.
43. Saslow D, Runowica CD, Solomon D, et al.: American Cancer Society guidelines for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002, 52:342-362.
44. Stanberry L, Spruance SL, Cunningham AL, et al.: Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Eng J Med 2002, 347:1652-1661.
45. Wald A, Corey L, Cone R, et al.: Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997, 99:1092-1097.
46. Corey L, Wald A, Parel R, et al.: Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004, 350:11-20.
47. Koutsky LA, Ault KA, Wheeler CM, et al.: A controlled trial of a human papillomavirus type 16 vaccine. N Eng J Med 2002, 347:1645-1651.
48. Blake DR, Kearney MH, Oakes JM, et al.: Improving participation in Chlamydia screening programs: perspectives of high risk youth. Arch Pediatr Adolesc Med 2003, 157:523-529.